News | April 03, 2025
Asahi Kasei Life Science begins operation
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 mn
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
The inspection has concluded with four observations
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Positions Curium as leading manufacturer of Lu-177 isotope
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Subscribe To Our Newsletter & Stay Updated
